Geriatric Exclusivity? Incentives For Research In Elderly Debated At National Academies Workshop
FDA principal deputy commissioner Amy Abernethy and former commissioner Robert Califf point to success of orphan drug and pediatric exclusivity incentives in spurring drug development for neglected populations.
You may also be interested in...
New incentives will most likely not be the immediate focus, but working group to explore ideas on enhancing understanding of drug effects in elderly populations will likely be formed by US FDA.
Former US FDA Commissioner Robert Califf remains eager to encourage broader use of real-world evidence – but his blunt, pessimistic read on the state of biopharma innovation is remarkable coming from a former FDA head.
In a report that offers a number of recommendations related to cancer care, an IoM committee suggests a plan for awarding six months of added patent life to new cancer drugs that are studied in the elderly.